Prcis: Ahmed glaucoma valve implantation is an effective and reliable intervention for neovascular glaucoma, demonstrating higher success and longer survival in proliferative diabetic retinopathy compared to central retinal vein occlusion. Age significantly impacts surgical outcomes.
Purpose: To evaluate and compare the surgical outcomes and prognostic factors of Ahmed glaucoma valve (AGV) implantation in neovascular glaucoma (NVG) secondary to proliferative diabetic retinopathy (PDR) and central retinal vein occlusion (CRVO).
Patients and methods: This retrospective study included 48 eyes of 46 patients with NVG due to PDR (n=28) or CRVO (n=18) who underwent AGV implantation. Patients with prior glaucoma surgery were excluded. All procedures were performed by a single glaucoma surgeon using a standardized long tunnel technique. Surgical success was defined as ≥20% intraocular pressure (IOP) reduction from baseline and IOP ≤ 21 mmHg without additional glaucoma surgery or vision loss to no light perception. Kaplan-Meier survival analysis assessed surgical success, and Cox regression identified failure risk factors.
Results: The mean surgical success duration was longer in PDR (45.87 months) than CRVO (38.68 months). One-year, two-year, and three-year success rates were 95.5%, 90.4%, and 90.4% in PDR, compared to 92.3%, 64.6%, and 55.4% in CRVO. Early complications, such as hyphema, were more frequent in PDR but not statistically significant. Tube exposure was observed in only one case (2.1% of total cases), which was in the CRVO group. Including the tube exposure case, tube explantation was performed in two patients (4.2% of total cases). Older age was a significant risk factor for failure (HR=1.066, P=0.049).
Conclusion: AGV implantation provides favorable long-term outcomes for NVG secondary to PDR and CRVO, with higher success rates in PDR. Careful patient selection and standardized surgical techniques remain critical for optimizing AGV outcomes in NVG.
扫码关注我们
求助内容:
应助结果提醒方式:
